Policy & Regulation
AbbVie secures EU approval for RINVOQ in polyarticular juvenile idiopathic arthritis
22 September 2026 - US biopharmaceutical company AbbVie (NYSE: ABBV) said on Tuesday it has received European Commission approval for RINVOQ (upadacitinib) to treat active polyarticular juvenile idiop...
Genentech reports positive Phase II results for enicepatide in type 2 diabetes
22 September 2026 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), on Tuesday reported positive topline Phase II results for enicepatide, an investigationa...
Pharming reports positive Phase II data for leniolisib in primary immunodeficiencies
22 September 2026 - Biopharmaceutical company Pharming Group N.V. (Euronext Amsterdam:PHARM) (NASDAQ:PHAR) on Tuesday announced positive topline Phase II data for leniolisib in genetically identifiabl...
Insmed's ARIKAYCE sNDA granted priority review by FDA
21 September 2026 - Biopharmaceutical company Insmed Incorporated (Nasdaq: INSM) disclosed on Monday that the US Food and Drug Administration has accepted its supplemental New Drug Application for ARI...
Precigen announces FDA platform technology designation for AdenoVerse
21 September 2026 - Biopharmaceutical company Precigen Inc (Nasdaq: PGEN) disclosed on Monday that it has received US Food and Drug Administration platform technology designation for its AdenoVerse im...
Enhertu recommended for EU approval in early HER2-positive breast cancer
21 September 2026 - British-Swedish biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (NYSE:AZN) and Japanese healthcare company Daiichi Sankyo Co Ltd (TYO:4568) announced on Monday that E...